Publications by authors named "Elmas Malvolti"

Article Synopsis
  • * The REVEAL-CKD study emphasizes the importance of early diagnosis and patient education, encouraging individuals to take an active role in their care for better health outcomes.
  • * The article presents insights from both patients and clinicians, discusses commonly used diagnostic tests, and offers suggestions for improving CKD detection and management by engaging patients and policymakers.
View Article and Find Full Text PDF

Background: People living with heart failure (HF) are particularly vulnerable after hospital discharge. An alliance between patient authors, clinicians, industry, and co-developers of HF programs can represent an effective way to address the unique concerns and obstacles people living with HF face during this period. The aim of this narrative review article is to discuss challenges and opportunities of this approach, with the goal of improving participation and clinical outcomes of people living with HF.

View Article and Find Full Text PDF

Purpose: This study was performed to assess symptom variability and its impact on morning activities in stable patients with severe COPD in the Middle East and Africa (MEA) countries.

Patients And Methods: Non-interventional, cross-sectional study (NCT03425760) in patients with severe COPD (GOLD 2015, C, or D categories). Symptom variability was assessed directly by interviewing the patient and using the Global Chest Symptoms Questionnaire (GCSQ).

View Article and Find Full Text PDF

Objective: The PROMPT study compared efficacy and tolerability of two treatment intensification strategies: adding saxagliptin or uptitrating metformin monotherapy, in patients with type 2 diabetes (T2D) and inadequate glycaemic control on a sub-maximal metformin dose.

Research Design And Methods: In this double-blind, 24-week study, metformin-tolerant patients with T2D on metformin monotherapy were randomised to receive fixed-dose metformin 1500 mg/day, plus either add-on saxagliptin 5 mg/day (SAXA-MET) or a two-step metformin uptitration (MET-UP) to a maximum dose (2500 mg/day).

Clinical Trial Registration: NCT01006590.

View Article and Find Full Text PDF